




United States Department of State

Washington, D.C. 20520

Memo

To: Dr. Sara Sofie Viksmoen Watle
Senior Physician
Department of Vaccines
Norwegian Institute of Public Health
Oslo, Norway

From: Robert Stern, MD 
SternR1@state.gov
Chief, Travel Medicine and Immunizations
Office of Medical Services
United States Department of State
Washington, DC

Date: May 4, 2016

Re: Meningococcal A,C,Y,W135 conjugate vaccines

This notice is written to confirm that Nimenrix® is a meningococcal A,C,Y,W-135 conjugate vaccine used to protect against four groups of *Neisseria meningitidis*, group A, group C, group Y and group W-135. Furthermore, Nimenrix (manufactured by Pfizer) is approved for use by the European Medicines Agency, which is similar to the US FDA. Nimenrix is registered and approved for sale in 61 countries across the European Economic Area, Canada, and Australia.

American children living in Europe have been successfully vaccinated with Nimenrix in the Health Units of US Embassies. At the age of 11-12 years old, and again at the age of 16-18 years old, American children living with their parents (who work as Diplomats in US Embassies) in Europe visit the Embassy Health Units to receive their scheduled vaccines. In countries where Menactra and Menveo (the FDA-approved meningococcal A,C,Y,W-135 conjugate vaccines) are unavailable, Nimenrix is used as the meningococcal vaccine and the children are considered adequately vaccinated after Nimenrix administration. These American children are not in need of additional meningococcal vaccine administration against *Neisseria meningitidis*, group A, group C, group Y and group W-135 after receiving the Nimenrix vaccine.